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Introduction {#sec1}
============

Telomeres are heterochromatic structures at the ends of chromosomes that consist of tandem repeats of the TTAGGG sequence bound by a protective six-protein complex known as shelterin ([@bib21]). Shelterin encompasses TRF1, TRF2, RAP1, TPP1, TIN2, and POT1, and all of them, except for RAP1, are essential for telomere protection ([@bib20], [@bib22]). In particular, shelterin-bound telomeres protect chromosome ends from degradation and repair activities in this manner preventing end-to-end chromosome fusions and ensuring chromosome stability ([@bib20]). Telomeres shorten throughout the lifespan of organisms associated to cell division owing to the so-called end replication problem, eventually jeopardizing tissue regeneration and organismal viability ([@bib15]). Telomere shortening can be compensated through *de novo* addition of telomeric repeats by telomerase, a reverse transcriptase composed of a catalytic subunit (TERT) and an RNA component (Terc), which is used as template for the synthesis of telomeric repeats ([@bib12]). Telomerase is highly active in pluripotent stem cells during embryonic development; however, it is silenced in the majority of differentiated cells after birth, thus leading to telomere shortening with aging ([@bib24]). Telomeres can also be elongated by an alternative mechanism known as alternative lengthening of telomeres (ALT), which is based on homologous recombination ([@bib6]).

Telomeres are considered as potential anti-cancer targets ([@bib13]). Cancer cells are known for their high proliferation rate, which induces a rapid telomere shortening followed by activation of DNA damage response (DDR) pathways that can lead to apoptosis or senescence. Any neoplastic cell should overcome these barriers to achieve an unlimited replicative potential, which in turn relies on telomere maintenance mechanisms ([@bib13]). In fact, more than 90% human tumors aberrantly over-express telomerase ([@bib19], [@bib36]), whereas the remaining telomerase-negative tumors activate ALT ([@bib6], [@bib2]).

Most studies aiming to target telomeres in cancer have focused on telomerase inhibition as therapeutic approach to prevent telomere elongation in cancer cells ([@bib14]). Indeed, telomerase is heavily mutated in many different cancer types, and telomerase activation is seen in 90%--95% of all tumor types ([@bib19], [@bib36], [@bib18]).The most advanced anti-telomerase drug is GRN163L, also called imetelstat ([@bib14]). However, both mouse models and human clinical trials have shown the limitations of this strategy, as the anti-tumorigenic effect is only achieved when telomeres reach a critically short length ([@bib10], [@bib29]) and this effect is lost in the absence of the *p53* tumor suppressor gene, which is frequently mutated in cancer. In addition, telomerase inhibition may favor the activation of alternative telomere elongation mechanisms based on recombination as extensively shown in yeast and mammalian cells ([@bib6], [@bib2]).

Interestingly, not only telomerase but also shelterins are mutated in cancer. In this regard, we and others have found that POT1 is mutated in several types of sporadic and familial human cancers, including chronic lymphocytic leukemia ([@bib31]), familial melanoma ([@bib32], [@bib37]), Li-Fraumeni-like families with cardiac angiosarcomas ([@bib7]), glioma ([@bib1]), mantle cell lymphoma ([@bib38]), and parathyroid adenoma ([@bib26]). These studies highlight the possibility of targeting the shelterin complex as a novel and promising strategy to target telomeres in cancer, which would lead to a rapid telomere dysfunction independently of telomere length, thus avoiding the shortcomings of telomerase inhibition. Indeed, several studies demonstrate that TRF1 inhibition could represent an alternative to telomerase to target telomeres more efficiently. TRF1 directly binds TTAGGG telomeric DNA where it is essential for telomere protection ([@bib20], [@bib24]). *Trf1* genetic deletion *in vivo* induces a persistent DDR at telomeres, which is sufficient to block cell division and induce apoptosis or senescence in several mouse tissues, independently of telomere length ([@bib23], [@bib3], [@bib34], [@bib30]). Interestingly, TRF1 is over-expressed in adult stem cell compartments and in pluripotent stem cells, where it is essential to maintain tissue homeostasis and pluripotency, respectively ([@bib5], [@bib34]). Over-expression of TRF1 has been also reported in several types of cancers such as renal cell carcinoma ([@bib27]) and gastrointestinal tumors ([@bib16]). Furthermore, we have recently reported that induction of telomere uncapping by *Trf1* genetic depletion or chemical inhibition can effectively block the growth of very aggressive and rapidly growing lung tumors in *p53*-deficient *K-RasG12V* mice, in a manner that is independent of telomere length ([@bib9]), thus further supporting that TRF1 could be a good anti-cancer target for aggressive tumors. We recently validated this hypothesis using glioblastoma (GBM) mouse models in which we demonstrated that *Trf1* deletion blocks both tumor initiation and progression, showing great impact on mice survival ([@bib4]).

Given the promising results of TRF1 inhibition in two independent tumors types (i.e., lung cancer and glioblastoma), in the present work we aim to study the safety of long-term *Trf1* genetic deletion in wild-type (WT) and cancer-prone mouse models.

Results {#sec2}
=======

Whole-Body *Trf1* Deletion Does Not Affect Mouse Survival in the Context of Wild-Type or Cancer-Prone Mouse Models {#sec2.1}
------------------------------------------------------------------------------------------------------------------

Any potential anti-cancer target must fulfill the important requisite of not showing deleterious effects in healthy tissues or compromising organism viability. In line with this, we previously demonstrated that *Trf1* whole-body deletion in adult mice does not impair organismal viability over a 6-month follow-up period and only leads to mild loss of cellularity in highly proliferative tissues ([@bib9], [@bib4]). However, potential lifelong adverse effects of *Trf1* deletion in a healthy organism are still unknown. In addition, the long-term effects of *Trf1* deletion and the associated telomere damage in cancer-prone mouse models are unknown. Thus, here we set to study the long-term effects of *Trf1* whole-body deletion in three independent genetic backgrounds, including both WT and cancer-prone *Ink4Arf*^*−/−*^ and *p53*^*−/−*^ backgrounds. To this end, we took advantage of the *Trf1-*inducible knockout mice previously described by us ([@bib23]) to generate the following independent mouse cohorts, which allow for *Trf1* deletion upon tamoxifen administration in the diet: *Trf1*^*lox/lox*^ or *Trf1*^*+/+*^, hUBC-CreERT2, *Ink4Arf*^*−/−*^ mice; *Trf1*^*lox/lox*^ *or Trf1*^*+/+*^, hUBC-CreERT2, *p53*^*−/−*^ mice; and *Trf1*^*lox/lox*^ or *Trf1*^*+/+*^, hUBC-CreERT2 mice. Next, we induced *Trf1* deletion by administering tamoxifen in the diet at 6 weeks of age in the case of *p53*^*−/−*^ mice and at 10 weeks of age in the case of the *Ink4rf*^*−/−*^ and WT cohorts ([Figure 1](#fig1){ref-type="fig"}A). The tamoxifen diet was started earlier in the case of *p53*^*−/−*^ mice owing to their shorter lifespan due to earlier tumor development ([@bib17]). In all cases, the tamoxifen diet was maintained until the humane endpoint. At this time point (humane endpoint), we determined TRF1 levels in different mouse tissues by using immunofluorescence ([Methods](#sec4){ref-type="sec"}). In all genetic backgrounds, we observed that *Trf1*^*lox/lox*^ mice showed decreased TRF1 nuclear fluorescence foci in all the organs studied compared with control *Trf1*^*+/+*^ mice ([Figures 1](#fig1){ref-type="fig"}B--1D). In addition, we confirmed *Trf1* deletion by performing qRT-PCR ([Figures 1](#fig1){ref-type="fig"}E--1G) and PCR analysis ([Figures S1](#mmc1){ref-type="supplementary-material"}E--S1G) in multiple organs from *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice. Thus, long-term tamoxifen treatment can efficiently delete *Trf1* in different adult mouse tissues.Figure 1Analysis of *Trf1* Deletion in Multiple Organs(A) The different mouse cohorts started tamoxifen treatment at 6--10 weeks\' age. Mice were sacrificed at the human endpoint.(B) Quantification of nuclear TRF1 fluorescence in multiple mouse tissue after *Trf1* deletion in *Ink4Arf*-deficient background (right). Representative images (left). Scale bar, 5 μM.(C) Quantification of nuclear TRF1 fluorescence in multiple mouse tissue after *Trf1* deletion in *Ink4Arf*-deficient background (right). Representative images (left). Scale bar, 5 μM.(D) Quantification of nuclear TRF1 fluorescence in multiple mouse tissue after *Trf1* deletion in WT background (right). Representative images (left). Scale bar, 5 μM.(E--G) (E) qRT-PCR analysis of *Trf1* mRNA expression in *Ink4Arf*-deficient background. (F) qRT-PCR analysis of *Trf1* mRNA expression in *p53*-deficient background. (G) qRT-PCR analysis of *Trf1* mRNA expression in WT background. Data are represented as mean ± SEM. n represents number of mice. Statistical analysis: unpaired *t* test. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.See also [Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}.

To address whether long-term *Trf1* deletion was affecting telomere length, we performed quantitative telomere fluorescence *in situ* hybridization (FISH) analysis in intestinal sections from *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice. We observed that *Trf1* deletion only caused a significant decrease in intestinal telomere length in *Ink4Arf*^*−/−*^ mice ([Figure S2](#mmc1){ref-type="supplementary-material"}A).

Interestingly, we found that *Trf1* deletion did not significantly affect overall mouse survival in any of the genetic backgrounds studied (*Ink4Arf*-deficient, *p53-*deficient, and WT backgrounds) ([Figure 2](#fig2){ref-type="fig"}A). *Trf1*-deficient mice, however, showed skin abnormalities of different severities depending on the genetic background. In particular, in the *Ink4Arf*-deficient background, *Trf1* deletion caused severe hair graying, whereas this was not observed in the *p53*^*−/−*^ background ([Figure 2](#fig2){ref-type="fig"}B). In the *p53*^*−/−*^ background, *Trf1* deletion caused hair loss and skin wounds ([Figure 2](#fig2){ref-type="fig"}B). In the WT background, *Trf1* deletion caused the most severe skin phenotype, including both hair graying and hair loss ([Figure 2](#fig2){ref-type="fig"}B), suggesting that loss of the tumor suppressors was partially rescuing the phenotypes induced by *Trf1* deletion.Figure 2*Trf1* Deletion in *Ink4Arf*-Deficient, *p53*-Deficient, and Wild-Type Backgrounds Does Not Alter Mice Viability(A) Survival curve analysis of *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice in *Ink4Arf*-deficient, *p53*-deficient, and wild-type backgrounds.(B) Representative images of mice of the indicated genotypes.(C) Weight follow-up in females of the indicated genotypes.(D) Body weight follow-up in males of the indicated genotypes.Data are represented as mean ± SEM. n represents number of mice. Statistical analysis: unpaired t test, and log rank test. ns, no significant. ∗p \< 0.05, ∗∗∗p \< 0.001.

Longitudinal analysis of body weight also revealed that *Trf1* abrogation in the *Ink4Arf*-deficient background caused a slight but significant decrease in body weight at older ages (6 months of age) only in females ([Figures 2](#fig2){ref-type="fig"}C and 2D). Interestingly, this phenotype was not observed in *p53*-deficient male or female mice ([Figures 2](#fig2){ref-type="fig"}C and 2D), again suggesting a less severe phenotype in the in *p53*-deficient mice than in the *Ink4Arf*-deficient background. Finally, as the case of the skin, the most severe weight phenotype was observed when *Trf1* was deleted in the WT background, where both males and females showed a significant decrease in body weight, which was more severe in females ([Figures 2](#fig2){ref-type="fig"}C and 2D). In summary, full-body *Trf1* deletion did not impair mouse viability in any of the studied genetic backgrounds, although we could observe mild phenotypes like decreased body weight and hair graying or hair loss, which were of different severities in the different genetic backgrounds.

*Trf1* Genetic Deletion Induces Epithelial Abnormalities {#sec2.2}
--------------------------------------------------------

To further characterize the cellular phenotypes induced by *Trf1* deletion, we performed a full histological analysis of the different *Trf1*^*lox/lox*^ and *Trf1*^*+/+*^ mouse cohorts. In the case of the *Ink4Arf-*deficient background, we did not see any significant pathologies in the intestine, bone marrow, and the liver of *Trf1*-deleted mice compared with control mice ([Figure 3](#fig3){ref-type="fig"}A). However, 85% of *Trf1*^*lox/lox*^ *Ink4Arf*^*−/−*^ mice showed increased epithelial abnormalities compared with control mice ([Figure 3](#fig3){ref-type="fig"}A). We classified the skin lesions as "non-tumoral" and "pre-neoplastic lesions." "Non-tumoral" lesions included degenerative lesions, i.e., atrophy in both epidermis and hypodermis, dermal fibrosis, follicular atrophy, and proliferative lesions, i.e., hyperkeratosis. The pre-neoplastic lesions included cell depolarization and nuclear atypia (i.e., anisocariosis, anisocytosis, and giant nuclei). We found that *Trf1* deficiency in the *Ink4Arf-*deficient background caused a significant increase in both the percentage of mice with "non-tumoral" and "pre-neoplastic" lesions as well as in the number of these lesions per mouse ([Figures 3](#fig3){ref-type="fig"}B--3E). Although we did not find any overt intestinal pathologies in *Trf1*^*lox/lox*^ *Ink4Arf*-deficient mice, they showed a mild shortening of the intestinal microvilli ([Figure 3](#fig3){ref-type="fig"}F).Figure 3Histopathological Analysis in *Trf1*-Deficient *Ink4Arf*^−/−^ Mice(A) Percentage of mice with pathologies in skin, intestine, bone marrow, and liver after *Trf1* deletion.(B) Percentage of *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice with "non-tumoral" and "pre-neoplasic" skin lesions.(C) Number of "non-tumoral" and "pre-neoplasic" skin lesions per mice in the indicated genotypes.(D) Representative image of skin "non-tumoral" lesions. Scale bar, 50 μM.(E) Representative image of skin "pre-neoplasic" lesions. Scale bar, 10 μM.(F) Quantification of the length of the villi in *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice (right) and representative images (left). Scale bar, 50 μM. Data are represented as mean ± SEM. n represents number of mice. Statistical analysis: unpaired t test and chi-square test. ns, no significant. ∗∗∗p \< 0.001.

Interestingly, in the *p53*-deficient background, pathologies associated with *Trf1* deletion were detected in a wider range of tissues including the skin, intestine, stomach, esophagus, and testes, although the differences reached statistical significance only in the skin and the intestine ([Figure 4](#fig4){ref-type="fig"}A). In the case of the skin, *Trf1* deletion increased both the percentage of mice with "non-tumoral" and the "pre-neoplasic" lesions as well as the number of these lesions per mouse ([Figures 4](#fig4){ref-type="fig"}B and 4C). The most prevalent "non-tumoral" lesions included dermatitis, hyperkeratosis, and hyperplasia ([Figure 4](#fig4){ref-type="fig"}D). Regarding the pre-neoplastic lesions, *Trf1* deletion increased the presence of dysplasia, cell depolarization, malignant hyperplasia, and nuclear atypia ([Figure 4](#fig4){ref-type="fig"}E). Similar results were observed in the intestine, the stomach, and the esophagus. In particular, *Trf1* deletion significantly increased the number of pre-neoplastic lesions in the intestine ([Figure 4](#fig4){ref-type="fig"}F), including dysplasia, cell depolarization, and nuclear atypia ([Figure 4](#fig4){ref-type="fig"}G). The same tendency was observed in stomach and esophagus ([Figures 4](#fig4){ref-type="fig"}H and 4I), although it did not reach statistical significance. Regarding the reproductive organs, we found that 18% of *Trf1*^*lox/lox*^ mice suffered from azoospermia in the testes or follicular atrophy in the ovaries ([Figure 4](#fig4){ref-type="fig"}A).Figure 4Histopathological Analysis in *Trf1*-Deficient *p53*^−/−^ Mice(A) Percentage of mice with pathologies in skin, intestine, esophagus, stomach, and testes after *Trf1* deletion.(B) Percentage of *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice with "non-tumoral" and "pre-neoplasic" skin lesions.(C) Number of "non-tumoral" and "pre-neoplasic" skin lesions per mice of the indicated genotypes.(D) Representative image of skin "non-tumoral" lesions. Scale bar, 20 μM.(E) Representative image of skin "pre-neoplasic" lesions. Scale bar, 20 μM.(F) Number of intestinal "pre-neoplasic" lesions *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice.(G) Representative image of intestinal "pre-neoplasic" lesions.(H) Number of "pre-neoplasic" lesions in the esophagus and stomach of *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice.(I) Representative image of "pre-neoplasic" lesions in stomach and esophagus. Scale bar, 20 μM.Data are represented as mean ± SEM. n represents number of mice. Statistical analysis: unpaired t test and chi-square test. ns, no significant. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

Finally, we also determined the effects of *Trf1* deletion in a WT background. In this case, we observed a significant increase in pathologies in the skin and intestine, although it only reached statistical significance in the skin ([Figure 5](#fig5){ref-type="fig"}A). In fact, 100% of the *Trf1*-deficient mice showed an increase in skin pathologies ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, and contrary to the results obtained in cancer-prone models, all the pathologies found were "non-tumoral" ([Figures 5](#fig5){ref-type="fig"}B and 5C), including degenerative lesions like atrophy in both epidermis and hypodermis, dermal fibrosis and follicular atrophy, inflammatory lesions such as dermatitis, and proliferative lesion like benign hyperplasias and hyperkeratosis ([Figure 5](#fig5){ref-type="fig"}D).Figure 5Histopathological Analysis of *Trf1*-Deficient Mice in a Wild-Type Background(A) Percentage of mice with pathologies in skin, intestine, and kidney after *Trf1* deletion.(B) Percentage of *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice with "non-tumoral" and "pre-neoplasic" skin lesions.(C) Number of "non-tumoral" and "pre-neoplasic" skin lesions per mice of the indicated genotypes.(D) Representative image of skin "non-tumoral" lesions. Scale bar, 50 μM. Data are represented as mean ± SEM. n represents number of mice. Statistical analysis: unpaired t test and chi-square test. ns, no significant. ∗∗p \< 0.01, ∗∗∗p \< 0.001.

In summary, *Trf1* deletion increased the presence of non-tumoral lesions in the skin of *Ink4Arf*-deficient, *p53*-deficient, and WT mice. However, the increase in "pre-neoplasic" lesions was only observed in the absence of the tumor suppressors *Ink4Arf* and *p53,* but not when *Trf1* was deleted in a WT background, suggesting that these tumor suppressors mediate some cellular effects of *Trf1* deletion.

*Trf1* Deletion Induces DNA Damage and Proliferation Defects, but Does Not Reduce Stem Cell Markers {#sec2.3}
---------------------------------------------------------------------------------------------------

*Trf1* deletion has been previously shown to induce a persistent DDR at telomeres, which can lead to senescence or apoptosis depending on the cell type ([@bib23], [@bib3], [@bib34], [@bib30]). Here, we set to address whether whole-body *Trf1* deletion caused increased DNA damage in the context of WT and tumor-prone models studied here. Given that the most affected tissue was the skin, we quantified the percentage of cells positive for the γH2AX DNA damage marker in skin sections from *Trf1*^*lox/lox*^ and *Trf1*^*+/+*^ mice in *Ink4Arf*-deficient, *p53*-deficient, and WT backgrounds by using immunohistochemistry ([Methods](#sec4){ref-type="sec"}). We found that in a *Ink4Arf*-deficient background, *Trf1*^*lox/lox*^ mice showed 12% γH2AX-positive skin cells compared with only 5% in the case of *Trf1*^*+/+*^ mice ([Figure 6](#fig6){ref-type="fig"}A). Interestingly, in a *p53*-deficient background, *Trf1*^*lox/lox*^ mice showed up to 53% of the skin cells positive for γH2AX compared with 6% in the *Trf1*^*+/+*^ controls ([Figure 6](#fig6){ref-type="fig"}A). In the case of a WT background, *Trf1*-deleted mice showed 18% of the skin cells positive for γH2AX positive compared with 3% in the *Trf1*^*+/+*^ controls ([Figure 6](#fig6){ref-type="fig"}A). To study whether the DNA damage was stemming from telomeres, we determined the so-called telomere-induced foci (TIF), by performing immuno-FISH analysis with 53BP1 as a marker of DNA damage and the telomeric FISH probe to locate telomeres in skin sections. Again, *Trf1* deletion only increased the percentage of cells with more than one TIF in the *p53*-deficient background ([Figure 6](#fig6){ref-type="fig"}B). Together, these findings suggest that *p53* deficiency is allowing for the accumulation of DNA-damaged cells in the skin of *Trf1*^*lox/lox*^ mice, whereas these cells are less frequent in the skin of *Ink4Arf*-deficient and WT backgrounds, in agreement with the known role of p53 in signaling telomere-induced DNA damage ([@bib8], [@bib23]).Figure 6*Trf1* Deletion Leads to DNA Damage And Proliferation Defects in *Ink4Arf*- and *p53*-Deficient Backgrounds(A) Representative images (up) and quantification (down) of γH2AX -positive cells in the hair follicles after *Trf1* deletion in *Ink4Arf*^*−/−*^*, p53*^*−/−*^, and wild-type backgrounds. Scale bar, 10 μM.(B) Representative images (up) and quantification (down) of percentage of cells with more than 1 TIF after *Trf1* deletion in the indicated genotypes. Scale bar, 5 μM.(C) Representative images (up) and quantification (down) of Ki67-positive cells in the basal layer after *Trf1* deletion in the indicated genotypes. Scale bar, 20 μM.(D) Representative images (up) and quantification (down) of Sox9 -positive cells in the hair follicles after *Trf1* deletion in the indicated backgrounds. Scale bar, 20 μM.Data are represented as mean ± SEM. n represents number of mice. Statistical analysis: unpaired t test*.* See also [Figure S3](#mmc1){ref-type="supplementary-material"}. ns, no significant. ∗p \< 0.05, ∗∗p \< 0.01, ∗∗∗p \< 0.001.

Next, we set to address whether *Trf1* deletion also resulted in cell proliferation defects in the skin. To this end, we quantified the percentage of cells positive for the Ki67 proliferation marker by using immunohistochemistry in skin sections from the different mouse cohorts. In the *Ink4Arf*-deficient background, we found a severe decrease in proliferation with only 10% of the basal layer cells positive for Ki67 compared with more than 20% in the control mice ([Figure 6](#fig6){ref-type="fig"}C). In contrast, in the absence of *p53*, *Trf1*^*lox/lox*^ mice showed a marked increase in proliferation reaching 60% of the basal layer cells being positive for Ki67 compared with 20% in the control counterparts ([Figure 6](#fig6){ref-type="fig"}C). In the WT background, however, we did not see significant differences in proliferation between the *Trf1*-deleted and control counterparts ([Figure 6](#fig6){ref-type="fig"}C). Again, these results suggest that the *p53* tumor suppressor represents a stronger barrier than the *Ink4Arf* tumor suppressor to prevent the proliferation of cells deficient for *Trf1* and with increased DNA damage, which in turn may favor the increased pre-neoplastic lesions in these backgrounds.

Finally, we determined whether *Trf1* deletion was affecting known skin stem cell makers. To this end, we quantified the percentage of cells positive for the Sox9 skin stem cell marker by using immunohistochemistry in skin sections from *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice. However, we did not observe significant differences in Sox9-positive cells in *Trf1*-deleted mice from any of the different genetic backgrounds ([Figure 6](#fig6){ref-type="fig"}D). As an independent tissue, we determined the percentage of Sox2-positive cells (a marker of neural stem cells) by immunohistochemistry in the brain, and again we did not observe any differences in the number of Sox2-positive cells between *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice in the different genetic backgrounds ([Figure S3](#mmc1){ref-type="supplementary-material"}A).

Tumors Appearing in *Trf1*-Deleted Mice Are Escapers and Express the TRF1 Protein {#sec2.4}
---------------------------------------------------------------------------------

The absence of both the *Ink4Arf* and the *p53* tumor suppressors has been widely linked to the appearance of spontaneous tumors in mice, including histiocytic sarcomas (HS), sarcomas, or lymphomas ([@bib17], [@bib35]). On the other hand, we have recently demonstrated that *Trf1* deletion has an anti-tumorigenic effect in the context of oncogene-driven tumors in mice by using both lung cancer and glioblastoma mouse models ([@bib9], [@bib4]). However, even though *Trf1* deletion has an anti-tumorigenic effect in oncogene-induced tumor models, it is also conceivable that DNA damage induced by *Trf1* deletion could promote tumorigenesis in the context of tumor suppressor-deficient mouse models. To explore this possibility, we studied spontaneous tumorigenesis in *Trf1*^*lox/lox*^ and *Trf1*^*+/+*^ mice, in both *Ink4Arf-* and *p53*-deficient backgrounds. To this end, we followed mice throughout their entire lifespan and studied the onset and severity of the tumors that appeared.

In a *Ink4Arf* background, *Trf1* deletion did not alter the percentage of mice with tumors ([Figure 7](#fig7){ref-type="fig"}A) or the tumor onset ([Figure 7](#fig7){ref-type="fig"}B). Interestingly, when looking at particular tumor types, we observed that *Trf1*-deleted mice showed a higher incidence of lymphomas (up to 66%) and a lower incidence of HS and sarcomas, although the two latter ones did not reach statistical significance ([Figures 7](#fig7){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}A). Although these findings may suggest increased tumorigenesis in the absence of *Ink4Arf*, analysis of TRF1 protein levels in tumors by immunofluorescence revealed that all the lymphomas and HS analyzed in *Trf1*-deficient mice showed normal TRF1 protein levels, indicating that they did not originate from *Trf1*-deleted cells ([Figure 7](#fig7){ref-type="fig"}D). The fact that we did not find a single tumor lacking TRF1 expression indicates that TRF1 deficiency impedes tumorigenesis in *Ink4Arf*-deficient background.Figure 7*Trf1* Deletion Blocks Tumorigenesis in *InkArf-*Deficient and *p53-*Deficient Mice(A) Percentage of mice with tumors at the human endpoint in *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^*InkArf-*deficient mice.(B) Tumor onset in the indicated genotypes.(C) Lymphoma, HS, and sarcoma incidences in *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^*InkArf-*deficient mice.(D) Quantification (right) and representative images (left) of nuclear TRF1 fluorescence in *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mouse tumors. Scale bar, 5 μM.(E) Percentage of mice with tumors at the human endpoint in *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^*p53-*deficient mice.(F) Tumor onset in the indicated genotypes.(G) Thymoma, sarcoma, and skin carcinoma incidence in *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^*p53-*deficient mice.(H) Quantification (right) and representative images (left) of nuclear TRF1 fluorescence in *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mouse tumors. Note that normal skin of *Trf1*^*+/+*^ mice was used as control for skin carcinomas. Scale bar, 5 μM.Data are represented as mean ± SEM. n represents number of mice. Statistical analysis: unpaired t test and chi-square test*.* See also [Figure S4](#mmc1){ref-type="supplementary-material"}. ns, no significant. ∗p \< 0.05.

In the case of the *p53*-deficient background, *Trf1*-deleted mice reduced the percentage of mice with tumors from 90% (*Trf1*^*+/+*^) to 68% (*Trf1*^*lox/lox*^) ([Figure 7](#fig7){ref-type="fig"}E), although this difference did not reach statistical significance. Similarly, we did not observe any differences in tumor onset between *Trf1*^*+/+*^ and *Trf1*^*lox/lox*^ mice ([Figure 7](#fig7){ref-type="fig"}F). When looking at individual tumor types, we observed a tendency to show decreased thymic lymphomas and sarcomas in the *Trf1*^*lox/lox*^ mice ([Figures 7](#fig7){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}B), although the difference did not reach statistical significance. In contrast, we observed a significant increase in skin carcinomas in *Trf1*^*lox/lox*^ mice ([Figures 7](#fig7){ref-type="fig"}G and [S4](#mmc1){ref-type="supplementary-material"}B). However, TRF1 immunofluorescence analysis indicated that all the tumors appearing in *Trf1*^*lox/lox*^ mice were escapers, as no differences were found in TRF1 protein levels compared with the *Trf1*^*+/+*^ mice ([Figure 7](#fig7){ref-type="fig"}H). Note that for skin carcinomas we used normal skin of *Trf1*^*+/+*^ mice as control as these types of tumors were not found in control mice.

These findings indicate that *Trf1* deficiency completely blocks tumorigenesis in the context of mice deficient for two major tumor suppressors, *Ink4Arf* and *p53*.

Discussion {#sec3}
==========

Therapeutic strategies based on telomerase inhibition have been the focus of cancer treatments for some years, as telomere maintenance above a minimum length is necessary for cancer cell growth ([@bib19], [@bib13]). However, both telomerase abrogation in mouse models and human clinical trials with telomerase inhibitors have shown limitations, most likely owing to the fact that a telomerase inhibitor would be only effective when telomeres are short and tumors are heterogeneous in terms of telomere length as well as can activate telomerase-independent mechanisms for telomere length maintenance or ALT ([@bib8], [@bib11], [@bib10], [@bib28], [@bib29], [@bib25]).

We have recently proposed an alternative strategy for targeting the telomeres independently of telomere length by directly targeting the telomere-protective complex shelterin through TRF1 inhibition. TRF1 is an essential component of shelterin that directly binds TTAGGG telomeric DNA repeats ([@bib20], [@bib24]). *Trf1* genetic deletion *in vivo* induces a persistent DDR at telomeres, which is sufficient to block cell division and induce apoptosis or senescence in several mouse tissues ([@bib23], [@bib3], [@bib34], [@bib30]). Interestingly, induction of telomere uncapping by *Trf1* genetic depletion or TRF1 chemical inhibition can effectively block the growth of very aggressive and rapidly growing lung tumors in *p53*-deficient *K-RasG12V* mice, in a manner that is independent of telomere length ([@bib9]), as well as can block both tumor initiation and progression in glioblastoma mouse models ([@bib4]).

Any potential anti-cancer target must fulfill the important requisite of not showing deleterious effects in healthy tissues or compromising organism viability. In line with this, we had previously demonstrated that short-term *Trf1* full-body deletion does not impair organism viability or cognitive functions and only affects slightly the highly proliferative tissues ([@bib9], [@bib4]). However, the long-term effects of *Trf1* deletion are still unknown.

Here we set to address the long-term effects of *Trf1* whole-body deletion in three different genetic backgrounds, including WT mice and the cancer-prone *Ink4Arf*^*−/−*^ and *p53*^*−/−*^ mouse models. We show that full-body *Trf1* deletion does not impair mouse viability in any of the studied genetic backgrounds, although we could observe mild phenotypes like decreased body weight and hair graying or hair loss, which were more severe in the WT background. In all the studied genetic backgrounds the most affected tissue was the skin. In fact, *Trf1* deletion increased the presence of "non-tumoral," mainly degenerative, lesions in the skin in all the studied backgrounds. Interestingly, we also observed an increase in pre-neoplastic lesions, but only in the absence of the tumor suppressors *Ink4Arf* and *p53*. At the cellular level, we observed that *Trf1* deletion induced different degrees of DNA damage in the skin of all genetic backgrounds although we only observed increased proliferation in the case of the *p53-*deficient background, in line with the known role of *p53* in signaling proliferation arrest in the presence of dysfunctional telomeres. Importantly, we did not observe significantly decreased stem cell markers in the skin or the brain upon conditional *Trf1* deletion, suggesting that tissue homeostasis is largely preserved upon *Trf1* deletion, in agreement with normal survival of *Trf1*-deleted mice in all genetic backgrounds.

We previously showed that *Trf1* deletion can block the growth of oncogene-driven, aggressive lung and glioblastoma tumors by inducing DNA damage at chromosome ends ([@bib9], [@bib4]). However, it was still unclear whether persistent *Trf1* deletion in the absence of an oncogenic driver could eventually lead to a high genomic instability and promote tumorigenesis. To explore this idea, we studied spontaneous tumorigenesis in *Trf1*^*lox/lox*^ and *Trf1*^*+/+*^ mice, in both *Ink4Arf-* and *p53*-deficient backgrounds. The absence of both the *Ink4Arf* and the *p53* tumor suppressors has been widely linked to the appearance of spontaneous tumors in mice, including HS, sarcomas, or lymphomas ([@bib17], [@bib35]). The results described here clearly indicate that *Trf1* deletion does not increase the percentage of mice with tumors in the absence of the tumor suppressors, although for certain tumor types, like lymphomas in the *Ink4Arf*-deficient background and skin carcinomas in the case of the *p53*-deleted mice, we found an increased incidence upon *Trf1* deletion. However, analysis of TRF1 protein levels in these tumors revealed that they were not deficient for TRF1 as they showed normal TRF1 protein levels, indicating that they did not originate from *Trf1*-deleted cells. The fact that no tumors lacking TRF1 expression were found suggests that TRF1 is essential for tumorigenesis in both *Ink4Arf-*deficient and *p53*-deficient backgrounds.

In light of these findings, one could argue that TRF1 inhibition in cancer could be advantageous compared with classical chemotherapies that are known to induce severe DNA damage, as well as induction of premature aging effects and of secondary tumors. In summary, these findings support that there is a therapeutic window for targeting TRF1 in cancer treatment.

Limitations of the Study {#sec3.1}
------------------------

The limitation of this study is that Cre-mediated *Trf1* deletion is not 100% in every organ, as reported by the immunofluorescence data. Thus, it should be considered that the observed phenotype is the consequence of a 50%--70% *Trf1* deletion.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods and Figures S1--S4
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